Bronchodilation and smoking interaction in COPD: A cohort pilot study to assess cardiovascular risk

Respiration

Volumn 83, Issue 2, 2012, Pages 125-132

  Van Dijk, Wouter D ^a   Lenders, Jacques W M ^a,b   Holtman, Joran ^a   Grootens, Joke ^a   Akkermans, Reinier ^a   Heijdra, Yvonne ^a   Van Weel, Chris ^a   Schermer, Tjard R J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Bronchodilator; COPD; Interaction; Ischemic cardiovascular disease; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; BRONCHODILATING AGENT; CARBASALATE CALCIUM; CLOPIDOGREL; DIPYRIDAMOLE; FENOTEROL; GLYCERYL TRINITRATE; IPRATROPIUM BROMIDE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; MONOCARD; NITRATE; SALBUTAMOL; TERBUTALINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; BRONCHODILATATION; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PILOT STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SAINT MARTIN (DUTCH); SPIROMETRY;

AGED; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; SMOKING;

EID: 84856491571     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000326921     Document Type: Article

References (28)

1. GOLD executive committee, GOLD science committee. GOLD Guidelines. 2009. www.goldcopd.com. Accessed August 2010.
2. Curkendall SM, Lanes S, de Luise C, Stang MR, She D, Goehring E Jr: Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol 2006;21:803-813.
3. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ: Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:549-555.
4. Cazzola M, Bettoncelli G, Sessa E, Cricelli C, Biscione G: Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010;80:112-119.
5. Schermer T, Heijdra Y, Zadel S, van den Bemt L, Boonman-de Winter L, Dekhuijzen R, Smeele I: Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med 2007;101:1355-1362.
6. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
7. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008.
8. Salpeter SR, Ormiston TM, Salpeter EE: Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-2321.
9. Singh S, Loke YK, Furberg CD: Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-1450.
10. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L; Interheart Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952.
11. Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, Diaz R, Rashed W, Freeman R, Jiang L, Zhang X, Yusuf S; Interheart Study Investigators: Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006;368:647-658.
12. Doll R, Peto R, Boreham J, Sutherland I: Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519.
13. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, Monson RR, Stason W, Hennekens CH: Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317:1303-1309.
14. Kuller LH, Ockene JK, Meilahn E, Wentworth DN, Svendsen KH, Neaton JD: Cigarette smoking and mortality. MRFIT Research Group. Prev Med 1991;20:638-654.
15. Sundblad BM, Larsson K, Nathell L: High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res 2008;10:883-890.
16. van Dijk WD, Heijdra Y, Scheepers PT, Lenders JW, van Weel C, Schermer TR: Interaction in COPD experiment (ICE): a hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease. Med Hypotheses 2010;74:277-280.
17. 2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3: CD001104.
18. Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M: Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2009.
19. Schermer TR, Smeele IJ, Thoonen BP, Lucas AE, Grootens JG, van Boxem TJ, Heijdra YF, van Weel C: Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J 2008;32:945-952.
20. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-586.
21. Smulders YM, Burgers JS, Scheltens T, van Hout BA, Wiersma T, Simoons ML: Clinical practice guideline for cardiovascular risk management in the Netherlands. Neth J Med 2008;66:169-174.
22. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, de Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL: Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-1381.
23. van Loenen AC, et al: Farmakotherapeutisch Kompas 2008/2009. Amstelveen, College voor Zorgverzekeringen, 2008.
24. Ploegstra MJ, Kampinga MA, Croon DH, Zijlstra F, van der Horst I C C: Medicatiegebruik conform de richtlijn op de lange termijn. Ned Tijdschr Geneeskd 2010;154:A1971.
25. Sidney S, Sorel M, Quesenberry CP Jr, De-Luise C, Lanes S, Eisner MD: COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068-2075.
26. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, Jones PW: Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64:939-943.
27. van Dijk WD, Scheepers PT, Cremers R, Lenders JW, Klerx W, van Weel C, Schermer TR, Heijdra Y: A method to study the effect of bronchodilators on smoke retention in COPD patients: study protocol for a randomized controlled trial. Trials 2011;12:37
28. Beasley R, Weatherall M, Travers J, Shirtcliffe P: Time to define the disorders of the syndrome of COPD. Lancet 2009;374:670-672.